- Supported exchanges /
- AU /
- VBS.AU
Vectus Biosystems Ltd (VBS AU) stock market data APIs
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of renal fibrosis. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops Accugen consisting of AccuCal and RealCount software that enhance speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was incorporated in 2005 and is based in Rosebery, Australia.
Vectus Biosystems Ltd Financial Data Overview
| 0.08 | |
| 0.08 | |
| - | |
| 0.08 | |
| 0.08 | |
| 0.076-0.32 | |
| 4 260 K | |
| 53 253 K | |
| 1 139 K | |
| 0.908 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Vectus Biosystems Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 1 139 K
- EBITDA -2 270 585
- Earnings Per Share -0.04
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Vectus Biosystems Ltd Earnings via APIs
- Latest Release 2024-10-31
- EPS/Forecast NaN
Get Vectus Biosystems Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
